Hemogenyx Pharmaceuticals PLC
HEMO
Company Profile
Business description
Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
Contact
6 Heddon Street
LondonW1B 4BT
GBRE: headquarters@hemogenyx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,853.70 | 60.20 | -0.76% |
| CAC 40 | 7,104.80 | 21.22 | -0.30% |
| DAX 40 | 20,374.10 | 188.63 | -0.92% |
| Dow JONES (US) | 40,212.71 | 619.05 | 1.56% |
| FTSE 100 | 7,964.18 | 50.93 | 0.64% |
| HKSE | 20,914.69 | 232.91 | 1.13% |
| NASDAQ | 16,724.46 | 337.14 | 2.06% |
| Nikkei 225 | 33,585.58 | 1,023.42 | -2.96% |
| NZX 50 Index | 12,019.13 | 182.30 | -1.49% |
| S&P 500 | 5,363.36 | 95.31 | 1.81% |
| S&P/ASX 200 | 7,646.50 | 63.10 | -0.82% |
| SSE Composite Index | 3,238.23 | 14.59 | 0.45% |